X4 Pharmaceuticals
XFOR
56 hedge funds and large institutions have $58.3M invested in X4 Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 5 closing their positions.
310% more capital invested
Capital invested by funds: $14.2M → $58.3M (+$44.1M)
240% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 5
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
14% more funds holding
Funds holding: 49 → 56 (+7)
0.16% more ownership
Funds ownership: 1.74% → 1.9% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
44% less call options, than puts
Call options by funds: $123K | Put options by funds: $221K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.51M |
| 2 |
O
OrbiMed
New York
|
+$4.21M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$3.88M |
| 4 |
Axa
Paris,
France
|
+$3.43M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.28M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$140K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$52.1K |
| 4 |
VF
Virtu Financial
New York
|
-$20K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CA
51
Clearstead Advisors
Cleveland,
Ohio
| $4K | – | – | – |
|
|
HNWAG
52
High Net Worth Advisory Group
Naples,
Florida
| $2K | – | – | – |
|
53
Rockefeller Capital Management
New York
| $1K | – | – | – |
|
54
Wells Fargo
San Francisco,
California
| $1K | +$449 | +13 | +217% |
|
55
BNP Paribas Financial Markets
Paris,
France
| $15 | – | – | – |
|
|
56
Citadel Advisors
Miami,
Florida
| – | -$52.1K | -1,508 | Closed |
|
|
VF
57
Virtu Financial
New York
| – | -$20K | -680 | Closed |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| – | -$5K | -188 | Closed |
|
|
CG
59
Cutler Group
San Francisco,
California
| – | -$587 | -17 | -50% |
|
60
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$104 | +3 | New |
|
XFOR Hedge Fund Activity: Q3 2022 in Review
56 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2022, worth a combined $58.3M — up 310% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XFOR positions and 5 closed out — a net gain of 8 holders — while 17 added to existing stakes and 5 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $7.51M. The largest seller was Ikarian Capital, cutting an estimated $1.28M.
- 56 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2022, up from 49 in Q2 2022.
- Funds reported $58.3M of X4 Pharmaceuticals stock for Q3 2022, up 310% quarter-over-quarter.
- 13 funds opened new X4 Pharmaceuticals positions in Q3 2022 and 5 closed out, a net change of +8 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2022 was NEA Management Company, an estimated $7.51M added.
- The largest X4 Pharmaceuticals seller in Q3 2022 was Ikarian Capital, an estimated $1.28M sold.
Based on aggregated 13F filings for Q3 2022.